Skip to main content
. 2019 Aug 19;84(4):849–860. doi: 10.1007/s00280-019-03914-2

Fig. 1.

Fig. 1

Plasma thiotepa and TEPA metabolite concentration following initial 24-h thiotepa IV infusion in pediatric patients with solid tumors or brain tumors on a linear (a) and semi-logarithmic (b) scale and following the initial 2-h thiotepa IV infusion in adult patients with malignant lymphoma on a linear (c) and semi-logarithmic (d) scale (pharmacokinetic analysis population). TEPA triethylene phosphoramide